IL6 and COVID-19: In this regard, probably some of the reasons why this has been limited are because it has been reported that COVID-19 patients display variable levels of IL-6, and the association of secondary infections with immunomodulators such as tocilizumab also is a common risk that has been identified [47,56,57,59].